Qyuns Therapeutics Co (HKSE:02509) ROCE %: 78.40% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02509 Qyuns Therapeutics Co Ltd HKSE:02509
9 GF Score
Price HK$17.64
! 5 Warning Signs
View Full Analysis

What is Qyuns Therapeutics Co ROCE %?

Qyuns Therapeutics Co HKSE:02509 -1.84% 9 ROCE % is 78.40% as of Dec. 2025. GuruFocus rates HKSE:02509 with a GF Score™ of 9/100. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Qyuns Therapeutics Co's annualized ROCE % for the quarter that ended in Dec. 2025 was 78.40%.

Qyuns Therapeutics Co  (HKSE:02509) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Qyuns Therapeutics Co ROCE % Related Terms

Qyuns Therapeutics Co ROCE % Historical Data

* Premium members only.

The historical data trend for Qyuns Therapeutics Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qyuns Therapeutics Co ROCE % Chart

Qyuns Therapeutics Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
-40.96 -29.27 -68.37 -58.76 40.03

Qyuns Therapeutics Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial -90.74 -54.40 -50.23 -6.69 78.40
HKSE:02509
9GF Score
Qyuns Therapeutics Co Ltd HKSE:02509
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Qyuns Therapeutics Co ROCE % Calculation

Qyuns Therapeutics Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=360.797/( ( (1050.458 - 459.271) + (1767.92 - 556.498) )/ 2 )
=360.797/( (591.187+1211.422)/ 2 )
=360.797/901.3045
=40.03 %

Qyuns Therapeutics Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=766.738/( ( (1237.509 - 493.015) + (1767.92 - 556.498) )/ 2 )
=766.738/( ( 744.494 + 1211.422 )/ 2 )
=766.738/977.958
=78.40 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 78.40% mean?
Qyuns Therapeutics Co (HKSE:02509) has a ROCE % of 78.40% as of Dec. 2025.
Is Qyuns Therapeutics Co's ROCE % too high?
Qyuns Therapeutics Co's current ROCE % is 78.40%. Overall, Qyuns Therapeutics Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Qyuns Therapeutics Co's ROCE % compare to VRTX and REGN?
Qyuns Therapeutics Co's ROCE % of 78.40% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Qyuns Therapeutics Co's current ROCE % is 78.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qyuns Therapeutics Co stock overvalued right now?
Qyuns Therapeutics Co (HKSE:02509) has a current ROCE % of 78.40%. The current ROCE % is 78.40%. Qyuns Therapeutics Co's overall GF Score™ is 9/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Qyuns Therapeutics Co (HKSE:02509), the current ROCE % is 78.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Qyuns Therapeutics Co Business Description

Address No. 907 Yaocheng Avenue, Room 1310, Building 1, Taizhou, Jiangsu, CHN
Qyuns Therapeutics Co Ltd is a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline. It has built a pipeline that covers the four disease areas in the field, including skin, rheumatic, respiratory, and digestive diseases. The group is principally engaged in the research and development, manufacturing, and commercialisation of biologic therapies for autoimmune and allergic diseases. Key revenue is generated from the PRC.
9GF Score

Get the complete analysis for HKSE:02509

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$17.64
Price